Brentuximab vedotin

Drug Profile

Brentuximab vedotin

Alternative Names: ADC SGN 35; Adcetris; Anti-CD30 Antibody-Drug Conjugate SGN-35; Anti-CD30 Monoclonal Antibody-MMAE SGN-35; Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35; cAC10-vcMMAE; SGN-35

Latest Information Update: 21 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Seattle Genetics; Stanford University
  • Developer Bristol-Myers Squibb; Celgene Corporation; Dana-Farber Cancer Institute; Fondazione Italiana Linfomi; Fox Chase Cancer Center; Lymphoma Academic Research Organisation; Massachusetts General Hospital; National Cancer Institute (USA); Seattle Genetics; Stanford University; Takeda; Takeda Oncology
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hodgkin's disease; Non-Hodgkin's lymphoma; Anaplastic large cell lymphoma; Peripheral T-cell lymphoma; Cutaneous T cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaplastic large cell lymphoma; Hodgkin's disease
  • Preregistration Cutaneous T cell lymphoma
  • Phase III T cell lymphoma
  • Phase II Diffuse large B cell lymphoma; Germ cell and embryonal neoplasms; Mesothelioma; Mycosis fungoides; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Sezary syndrome
  • Phase I Graft-versus-host disease
  • Discontinued Leukaemia; Multiple myeloma; Solid tumours; Systemic lupus erythematosus

Most Recent Events

  • 16 Aug 2017 US FDA grants a PDUFA date of 16 Dec 2017 for brentuximab vedotin for Cutaneous T-cell lymphoma
  • 16 Aug 2017 US FDA grants priority review for the sBLA for brentuximab vedotin for Cutaneous T-cell lymphoma
  • 16 Aug 2017 US FDA accepts sBLA for brentuximab vedotin for Cutaneous T-cell lymphoma for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top